Analysts Set Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Price Target at $21.00

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) has been assigned an average recommendation of “Buy” from the six analysts that are presently covering the company, Marketbeat Ratings reports. Six investment analysts have rated the stock with a buy recommendation. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $21.00.

Several research analysts have recently issued reports on ARTV shares. HC Wainwright started coverage on Artiva Biotherapeutics in a research report on Monday, December 30th. They set a “buy” rating and a $20.00 price objective for the company. Needham & Company LLC reaffirmed a “buy” rating and set a $23.00 price objective on shares of Artiva Biotherapeutics in a research report on Wednesday, November 13th.

Institutional Trading of Artiva Biotherapeutics

Several institutional investors and hedge funds have recently made changes to their positions in ARTV. Charles Schwab Investment Management Inc. purchased a new stake in shares of Artiva Biotherapeutics in the 3rd quarter valued at about $623,000. BNP Paribas Financial Markets purchased a new stake in shares of Artiva Biotherapeutics in the 3rd quarter valued at about $42,000. MetLife Investment Management LLC purchased a new stake in shares of Artiva Biotherapeutics in the 3rd quarter valued at about $135,000. Acuta Capital Partners LLC purchased a new stake in shares of Artiva Biotherapeutics in the 3rd quarter valued at about $680,000. Finally, RTW Investments LP purchased a new stake in shares of Artiva Biotherapeutics in the 3rd quarter valued at about $2,300,000.

Artiva Biotherapeutics Price Performance

ARTV opened at $3.77 on Tuesday. Artiva Biotherapeutics has a 12 month low of $3.37 and a 12 month high of $17.31. The business has a fifty day moving average price of $7.20 and a 200 day moving average price of $10.31.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.